Clinical trial
A Safety Study of ABI-007 for In-Stent Restenosis
NCT00093223 · Celgene, Industry · Completed
Key facts
| NCT number | NCT00093223 |
|---|---|
| Title | A Safety Study of ABI-007 for In-Stent Restenosis |
| Official title | A Phase II Safety Study of Systemic Nanoparticle Paclitaxel (ABI-007)for In-Stent Restenosis |
| Lead sponsor | Celgene, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Angina Pectoris, Coronary Artery Disease |
| Intervention type | Drug |
| Interventions | Paclitaxel Nanoparticle Albumin Bound |
| Enrollment | 76 |
| Start date | Sep 1, 2001 |
| Primary completion | Dec 1, 2007 |
| Completion | Dec 1, 2007 |
| First posted | Oct 7, 2004 |
| Last update posted | Nov 18, 2019 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: